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Both psychostimulants and antidepressants target monoamine transporters and, as a consequence,
augment monoamine transmission. These two groups of drugs also increase motor activity in preclinical
behavioural screens for antidepressants. Substance P-preferring receptor (NK1R) antagonists similarly
increase both motor activity in these tests and monoamine transmission in the brain. In this article, the
neurochemical and behavioural responses to these three groups of drugs are compared. It becomes
evident that NK1R antagonists represent a distinct class of compounds (‘motor disinhibitors’) that differ
substantially from both psychostimulants and antidepressants, especially during states of heightened
arousal or stress. Also, all three groups of drugs inﬂuence the activation of voltage-gated Ca(v)1.2 and
Ca(v)1.3 L-type channels (LTCCs) in the brain, albeit in different ways. This article discusses evidence that
points to disruption of these functional interactions between NK1R and LTCCs as a contributing factor in
the cognitive and behavioural abnormalities that are prominent features of Attention Deﬁcit Hyperac-
tivity Disorder (ADHD). Arising from this is the interesting possibility that the hyperactivity and
impulsivity (as in ADHD) and psychomotor retardation (as in depression) reﬂect opposite poles of a
behavioural continuum. A better understanding of this pharmacological network could help explain why
psychostimulants augment motor behaviour during stress (e.g., in preclinical screens for antidepressants)
and yet reduce locomotor activity and impulsivity in ADHD.
This article is part of the Special Issue entitled ‘CNS Stimulants’.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The substituted phenylalkylamines, d-amphetamine and
methylphenidate, are psychostimulants that bind preferentially
to noradrenaline (NET) and dopamine (DAT) transporters. D-
Amphetamine is also a substrate for the translocation site on the
transporter and so competes with noradrenaline and dopamine for
uptake (Fleckenstein et al., 1999). The tropane alkaloid, cocaine, is
another psychostimulant that blocks monoamine uptake, espe-
cially serotonin by comparison with either d-amphetamine or
methylphenidate (Bosy and Ruth, 1989; Fleckenstein et al., 1999),
but neither cocaine nor methylphenidate is a substrate for
translocation.Ltd. This is an open access articleSimilarly, most antidepressants bind to monoamine trans-
porters and inhibit uptake of these neurotransmitters, especially
noradrenaline and serotonin (Table 1). In this respect, the phar-
macodynamics of psychostimulants overlap with antidepressants
and so it is not surprising that these two classes of drugs produce
similar responses in preclinical screens for antidepressants (e.g., the
swim test and mouse tail-suspension test: Porsolt et al., 1978; Steru
et al., 1987; Cryan et al., 2005). Most of these procedures evaluate
the effects of drugs on the motor response to stress (rather than
‘depression-like’ behaviour), which is strongly inﬂuenced by
monoamine transmission. The positive behavioural response to
d-amphetamine in these screens is not entirely spurious. In the pre-
DSM era, this drug was used to treat ‘depression’, especially when
the illness involved prominent ‘fatigue’: this could suggest that
d-amphetamine relieves deﬁcits in motor motivation and activity,
which is a common feature of depression, rather than improves
affective state (see: Rasmussen, 2006 and Section 6).under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Changes in extracellular monoamines in the prefrontal cortex following acute administration of psychostimulants, antidepressants or NK1R antagonists.
Dopamine Noradrenaline Serotonin
Psychostimulants Amphetamine [[ [[ [ Rowley et al., 2014
Methylphenidate [[ [[ Koda et al., 2010
Cocaine [[ [ [[ Shen et al., 2004; Pan et al., 1995; Pum et al., 2007
Antidepressants [ [[ [[ Jordan et al., 1994; Kobayashi et al., 2008
NK1R antagonists Low arousal states [ [ [ Sections 2.2e2.4 (this article)
High arousal states Y Y [[
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is still a ﬁrst-line treatment for Attention Deﬁcit Hyperactivity
Disorder (ADHD), along with methylphenidate. Atomoxetine, a
preferential noradrenaline reuptake inhibitor, is also endorsed as
an effective treatment for ADHD. This raises interesting questions
about neurobiological factors that are common to psychostimu-
lants, antidepressants and drugs used to treat ADHD, which are
discussed later.
Antagonists of the neurokinin-1 receptor (NK1R), for which
substance P is the preferred endogenous ligand, comprise another
group of compounds that increase motor activity in preclinical
screens (e.g., Rupniak et al., 2001; Dableh et al., 2005; Yan et al.,
2010). Not only do they resemble psychostimulants and antide-
pressants in these behavioural procedures, but they also increase
the concentration of extracellular monoamines in the brain (espe-
cially serotonin: see below). On the basis of such evidence, NK1R
antagonists have been investigated for antidepressant activity, but
none has proved effective for this clinical indication so far.
However, early research of NK1R antagonists ﬂagged the prob-
lem that the compound, CP 96345, binds to voltage-gated, L-type
Ca2þ(v) channels (‘LTCCs’: Schmidt et al., 1992; Guard et al., 1993) as
well as NK1R. It has long been acknowledged that this non-speciﬁc
binding to LTCCs induces behavioural changes that resemble the
response to antidepressants (and psychostimulants) in preclinical
screens (Rupniak et al., 2001; Rupniak and Jackson, 1994). This
binding to LTCCs is shared by many NK1R antagonists: those for
which details have been published are listed in Table 2. However,
two compounds that have beenwidely used in preclinical research,
(S) GR 205171 and (S) SR 140333, can be regarded as selective NK1R
antagonists because their binding afﬁnity for the human NK1R is
approximately 105-fold higher than for LTCCs.
Against this background, it is interesting to appraise the extent
to which the pharmacology of NK1R antagonists resembles that of
psychostimulants and antidepressants, versus the possibility that
they represent a novel class of compounds with a distinct phar-
macological proﬁle. In so doing, this article will also consider how
LTCCs could modify the neurochemical and behavioural responses
to these three groups of compounds. The ﬁnal sections will discuss
the therapeutic implications of functional interactions between
LTCCs and NK1R antagonists in the light of evidence that a deﬁcit in
activated NK1R in mice induces behavioural abnormalities that
resemble those seen in ADHD.
2. Psychostimulants, antidepressants and NK1 receptor
(NK1R) antagonists have distinct effects on extracellular
monoamines (Table 1)
2.1. Psychostimulants and antidepressants augment serotonergic,
noradrenergic and dopaminergic transmission
It is well established that acute systemic administration of the
psychostimulants, cocaine, methylphenidate or d-amphetamine,
increases the extracellular accumulation of monoamines in theforebrain, especially the catecholamines, noradrenaline and dopa-
mine (Chen and Reith, 1994; Kuczenski et al., 1995; Rowley et al.,
2014). This action is thought to explain the motor arousing effects
of these drugs. Cocaine also causes a prominent increase in extra-
cellular serotonin, but methylphenidate is exceptional in that,
despite binding to the same site as cocaine on the dopamine
transporter, it has low afﬁnity for the serotonin transporter and
does not increase extracellular serotonin (Kuczenski and Segal,
1997; Pum et al., 2007; Fleckenstein et al., 1999).
Acute administration of antidepressants similarly causes an
(impulse-dependent) increase the extracellular concentration of
noradrenaline and serotonin in the forebrain, an action that is
consistent with their high afﬁnity for NET and/or SERT. However,
they also increase the concentration of extracellular dopamine (e.g.,
Kitaichi et al., 2010; Hudson et al., 2012; Cadeddu et al., 2013). In
most cases, this will be mediated indirectly though (synaptic) in-
teractions with serotonergic or noradrenergic neurones because,
with few exceptions, established antidepressants have negligible
afﬁnity for the DAT (see: Stanford, 1996a; Tatsumi et al., 1997).
An increase in the extracellular concentration of any of the
monoamines could inﬂuence motor activity (Auclair et al., 2004;
Rowley et al., 2014). However, an increase in dopaminergic trans-
mission is likely to be essential for preventing anhedonia, impaired
executive function and deﬁcits in motivation, all of which are key
features of depression (Argyropoulos and Nutt, 2013; Salamone and
Correa, 2012).
2.2. NK1R antagonists augment serotonin transmission
All reports indicate that a functional deﬁcit in NK1R increases
serotonergic transmission in the brain. For instance, acute systemic
administration of an NK1R antagonist increases extracellular se-
rotonin in the frontal cortex (e.g., GR 205171 or L 733060: Lejeune
et al., 2002; Guiard et al., 2005). An increase in serotonin release
was also found in a study of freely-moving mice with functional
ablation of the NK1R gene (NK1R/) (Froger et al., 2001). More-
over, local infusion of a NK1R antagonist into the forebrain
augmented the serotonergic response to stress (Ebner et al., 2008).
Again, there is no evidence that NK1R antagonists inhibit
monoamine transporters directly and so any increase in seroto-
nergic transmission presumably arises from an increase in impulse-
dependent release of transmitter. This could follow an increase in
the ﬁring-rate of raphé neurones projecting to forebrain regions,
which depends on input fromnoradrenergic neurons (Haddjeri and
Blier, 2008). However, it could also be mediated by preventing
NK1R in the terminal ﬁeld from activating a possible GABAergic
inhibition of serotonin release (Ebner et al., 2008) (Fig. 1).
Although NK1R antagonists have not fulﬁlled expectations as
antidepressants in their own right, they are still being developed as
adjuncts to established antidepressant treatments (e.g., Lelas et al.,
2013). However, it would probably be inadvisable to co-administer
an NK1R antagonist with a selective serotonin reuptake inhibitor
because the combined administration of drugs that increase
Table 2
Published reports of NK1R antagonist binding to different domains on LTCCs (pKi is speciﬁed when these are reported). ‘Yes’: substantial displacement of the radioligand by the
NK1R antagonist has been reported. ‘No’: no evidence of displacement of the radioligand by the NK1R antagonist has been reported.
Dihydropyridine [e.g. nifedipine] Benzothiazepines
[e.g. diltiazem]
Phenylalkylamine
[e.g verapamil]
References
CP 96345 CP 96345 reduces KD for
[3H]-nimodipine binding
Ki 22.5 nM
(rat cerebral cortex)
Yes Guard et al., 1993
McLean et al., 1993
CP 96345 No Yes Constantine et al., 1994
CP 96345 Yes Yes Yes McLean et al., 1993
CP 96345 Yes Yes Yes Lombet and Spedding, 1994
CP 96345 (Displacement of 0.25 nM
3[H]desmethoxyverapamil)
IC50: 41 nM McLean et al., 1993
CP 99994 (Displacement of 0.25 nM
3[H]desmethoxyverapamil)
IC50: 3.4 mM McLean et al., 1993
CP 99994 No No Yes Lombet and Spedding, 1994
GR 203040 No No No Beattie et al., 1995
GR 205171 [rat brain] pKi 5.6 pKi 5.6 pKi < 5 Gardner et al., 1996
L 733060 pKa: 8.3
IC50: 0.9 nM
IC50: 760 nM Harrison et al., 1995
RP 67580 Yes Yes Yes Lombet and Spedding, 1994
RP 67580 Yes Rupniak et al., 1993
RP 67580 (Displacement of 0.25 nM
3[H]desmethoxyverapamil)
210 nM McLean et al., 1993
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serotonin toxicity (Stanford and Stanford, 1999; Stanford et al.,
2010).2.3. NK1R antagonists blunt noradrenergic transmission during
arousal/stress
NK1R antagonists, like psychostimulants and established anti-
depressants, can augment noradrenergic transmission but reports
are not as consistent as those for serotonin. Acute administration of
the selective antagonist, GR 205171, increased extracellular
noradrenaline in rat forebrain in one study (Millan et al., 2001) but
not others (Renoldi and Invernizzi, 2006; Bert et al., 2002).Fig. 1. A schematic representation of a hypothetic network, incorporating functional
communication between NK1R and Ca(v)1.2 and Ca(v)1.3 channels, that modulates
motor activity and monoamine release during arousal/stress (e.g., the forced swim test
and tail suspension tests). The scheme, which is based on evidence described
throughout this article, could explain the overlap and key differences in the effects of
NK1R antagonists, antidepressants and psychostimulants on motor immobility and
monoamine release. Solid arrows indicate functional links for which experimental
evidence already exists. Dotted arrows indicate functional links that are implied, but
not conﬁrmed, by experimental evidence. Green ¼ activate; red ¼ inhibit.Neither GR 205171 nor functional ablation of the NK1R gene in
NK1R/mice affected extracellular noradrenaline in the prefrontal
cortex of freely-moving mice (Zocchi et al., 2003; Fisher et al.,
2007).
By contrast, chronic administration of the antagonist, L 760735,
induced burst-ﬁring of noradrenergic neurones in the locus
coeruleus of anaesthetized subjects (Maubach et al., 2002). This is
consistent with the greater concentration of extracellular
noradrenaline in the frontal cortex of anaesthetized NK1R/mice,
by comparison with their wildtypes (Herpfer et al., 2005; Fisher
et al., 2007).
These ﬁndings could suggest that noradrenaline release in-
creases only when there is a high degree of NK1R receptor occu-
pancy by antagonists. A second explanation, for which there is
some evidence (Fisher et al., 2007), is that a deﬁcit in activation of
NK1R blunts noradrenaline release in aroused animals. This pro-
posal is consistent with the ﬁnding that, unlike serotonin, GR
205171 prevented a stress-induced increase in extracellular
noradrenaline in the prefrontal cortex of freely-moving rodents
(Renoldi and Invernizzi, 2006; Ebner and Singewald, 2007). It also
ﬁts with evidence that arousing/stressful stimuli increase release of
substance P in the region of the locus coeruleus (Ebner and
Singewald, 2007), which increases the ﬁring-rate of noradren-
ergic neurones projecting from this nucleus (Guyenet and
Aghajanian, 1977).
As discussed in detail elsewhere (Yan et al., 2009), a lack of
functional NK1Rwould cause excessive noradrenergic transmission
during low states of arousal, but a deﬁcit in noradrenergic trans-
mission as arousal increases. This bidirectional disruption of central
noradrenergic transmission would impair the response to stressful
stimuli, including cognitive performance (‘selective attention’: see
also: Section 5).
2.4. NK1R antagonists blunt dopaminergic transmission during
arousal/stress
There is one report that dopamine release is increased by local
infusion of the non-selective NK1R antagonist, CP 96345, into the
rat striatum (Gygi et al., 1993). However, the majority of studies
have found that NK1R antagonists blunt dopamine transmission in
this brain region. For instance, the NK1R antagonist, L 732138,
prevented the dopamine-dependent decrease in the amplitude of
inhibitory postsynaptic currents (IPSCs) in nucleus accumbens
S.C. Stanford / Neuropharmacology 87 (2014) 9e1812in vitro, a response that is triggered by substance P (Kombian et al.,
2003). Local infusion of CP 96345, or systemic administration of
another antagonist, WIN 51708, similarly prevented the release of
acetylcholine from striatal interneurons mediated by dopaminergic
(D1) receptors. CP 96344, an enantiomer of CP 96345 that binds to
LTCCs, but not NK1R, did not prevent acetylcholine release, con-
ﬁrming that the response to CP 96345 can be attributed to antag-
onism of NK1R (Anderson et al., 1994).
So far, only one study has monitored striatal extracellular
dopamine in freely-moving NK1R/ mice (Yan et al., 2010). There
was no difference in basal efﬂux of dopamine in NK1R/ and
wildtypes but, notably, there was no increase in extracellular
dopamine in NK1R/ mice after treatment with d-amphetamine.
This echoes a report that local infusion of the NK1R antagonist, L
733060, into the rat striatum prevented an increase in extracellular
dopamine following systemic administration of cocaine (Loonam
et al., 2003) (See also: Section 4.4).
A similar pattern is evident from studies of the prefrontal cortex.
Systemic administration of GR 205171 increased baseline extra-
cellular dopamine in one study of rats (Lejeune et al., 2002) but not
another, using mice (Zocchi et al., 2003). However, as with
noradrenaline (see above), GR 205171 abolished the dopamine
response to arousal/stress (Renoldi and Invernizzi, 2006; Hutson
et al., 2004). This could explain why, in a microdialysis study of
freely-moving NK1R/ mice, extracellular dopamine in this
brain region was considerably lower than in wildtypes at baseline
and why the higher concentration of extracellular dopamine in
the wildtypes dissipated after administration of the antagonist,
RP 67580 (Yan et al., 2010) (Fig. 1).
2.5. Summary
A functional deﬁcit of NK1R seems to increase serotonin release,
especially during arousal/stress. However, there is no consistent
evidence that a lack of functional NK1R increases noradrenaline
release in freely-moving subjects and such a response is even more
uncertain for dopamine. Instead, the evidence suggests that NK1R
antagonists prevent dopamine and noradrenaline responses to
arousing/stressful stimuli as well as the striatal dopaminergic
response to psychostimulants. These are interesting ﬁndings, not
least because there is a well-established cross-sensitization of the
behavioural and neurochemical responses to repeated exposure to
stress and d-amphetamine (Antelman et al., 1980; Cruz et al., 2012),
which suggests that these two stimuli could have neurobiological
targets in common. Whether or not this is the case, any blunting of
central dopaminergic (and possibly noradrenergic) transmission by
NK1R antagonists distinguishes these drugs from psychostimulants
(e.g., Kuczenski et al., 1991; Lillrank et al., 1999).
Disruption of the catecholamine response to stress by NK1R
antagonists is also hard to reconcile with these compounds being
regarded as putative antidepressants. This is mainly because
established antidepressants augment, rather than reduce, mono-
amine responses to stress (e.g., Page and Lucki, 2002). Yet, NK1R
antagonists evidently increase motor activity in behavioural
screens for antidepressants: indeed, such a response in humans
could have beneﬁcial effects in treating psychomotor retardation in
depression. However, as explained above, dopaminergic trans-
mission makes an essential contribution to promoting motivation
and cognition, as well as preventing anhedonia, and so any
disruption of dopaminergic transmission by NK1R antagonists
would limit their efﬁcacy as antidepressants. Nevertheless, it is
possible that the blunting of dopaminergic transmission contrib-
utes to the antiemetic effects of apripetant and other NK1R an-
tagonists that are under development for this clinical application
(see: Yoshikawa et al., 2001).3. L-type Ca2D(v) channels (LTCCs) modulate monoamine
transmission
3.1. LTCC activation
LTCCs are voltage-gated Ca2þ channels (Ca(v)), which are
deﬁned pharmacologically by their high sensitivity to blockade by
dihydropyridines (see below). Two subtypes are expressed in
comparatively high densities in the brain: Ca(v)1.2 and Ca(v)1.3:
Hirota and Lambert, 1997). About 90% of these are a splice variant of
Ca(v)1.2 channels (Ca(v)1.2c; Sinnegger-Brauns et al., 2009), which
are found mainly on cell bodies and proximal dendrites of gluta-
matergic neurones in the cortex and striatum and, to a lesser
extent, the cerebellum (Hell et al., 1993).
Activation of LTCCs by BayK 8644 increases the release of all
three monoamines in the striatum (serotonin, noradrenaline and
dopamine: Sinnegger-Brauns et al., 2004; dopamine: Watanabe
et al., 1998; Maruya et al., 2003; but see: Kasim et al., 2006).
BayK 8644 also invariably augments Kþ-evoked release of serotonin
(e.g., Middlemiss and Spedding, 1985), noradrenaline (Ginap et al.,
1993; Sabrià et al., 1995) and dopamine (Woodward and Leslie,
1986; Watanabe et al., 1998) in the brain. This monoamine
response to BayK 8644 is likely to contribute to the increase in
motor activity on local infusion of this drug into the striatum (e.g.,
Watanabe et al., 1998; Maruya et al., 2003).
A series of important and highly relevant ﬁndings have emerged
from studies of genetically-altered mice with functionally inacti-
vated Ca(v)1.2 or Ca(v)1.3 channels. When Ca(v)1.2/ mice were
treated with BayK 8644, the release of noradrenaline was unaf-
fected and the dopamine response was reduced, but the serotonin
(and glutamate) response was abolished altogether. By contrast, in
Ca(v)1.3/ mice, the noradrenaline response was abolished and
the dopamine release was again blunted, but the serotonin and
glutamate response was unaffected (Sinnegger-Brauns et al., 2004).
It was inferred from this work that activated Ca(v)1.3 channels
augment noradrenaline release, whereas Ca(v)1.2 channel activa-
tion augments serotonin (and glutamate) release, and both chan-
nels augment dopamine release (see also: Sagala et al., 2012). It is
striking that Ca(v)1.3 channels promote release of catecholamines
(as do psychostimulants and antidepressants), whereas Ca(v)1.2
channels promote release of serotonin (as do empathogens and
antidepressants).
As well as their role in BayK 8644-evoked release of mono-
amines, LTCCs modulate dendritic release of serotonin (Colgan
et al., 2012; Trueta and De-Miguel, 2012). Serotonin released
through this process is thought to activate somatodendritic 5-HT1A
autoreceptors, which blunt serotonin release in the terminal ﬁeld
(Colgan et al., 2012). If, as is widely believed, activation of these 5-
HT1A autoreceptors delays the onset of antidepression, then pre-
vention of dendritic release of serotonin by LTCC-blockers should
reduce this therapeutic lag. Indeed, there is evidence that LTCC
blockers do have beneﬁcial effects in treating depression (Busquet
et al., 2010; Casamassima et al., 2010).
LTCCs also inﬂuence postsynaptic monoaminergic neurotrans-
mission. For instance, LTCC-opening underlies a prolonged after-
hyperpolarisation in the prefrontal cortex, which is triggered by
activation of dopaminergic (DRD2) receptors: this process regulates
the excitability of pyramidal neurons, which are the conduit for
cortical output (Gee et al., 2012). LTCCs contribute to a prolonged
after-hyperpolarisation, which is triggered by activation of
b1-adrenoceptors in the hippocampus (Zhang et al., 2013), and they
also modulate the response to activation of 5-HT2A receptors in the
nucleus accumbens (Burattini et al., 2013).
In short, LTCCs inﬂuence monoamine transmission through
several mechanisms, both up- and downstream of transmitter
S.C. Stanford / Neuropharmacology 87 (2014) 9e18 13release in the terminal ﬁeld. As discussed below, evidence suggests
that these processes modify animals’ motor motivation and
behaviour, especially during arousal/stress.
3.2. LTCC blockade
Three classes of drugs act as LTCC-blockers: dihydropyridines
(e.g., nifedipine and nimodipine); benzothiazepines (e.g., diltiazem)
and phenylalkylamines (e.g., verapamil). Dihydropyridines bind to
all LTCCs but preferential binding of the phenylalkylamine, verap-
amil, deﬁnes Ca(v)1.2 channels, whereas diltiazem is used to deﬁne
Ca(v)1.3 binding (see: Tuckwell, 2012). Some dihydropyridines
promote, rather than prevent, LTCC channel-opening (e.g., BayK
8644) but an equivalent spectrum of action, from full channel-
activators to full channel-blockers, has not been reported for ben-
zothiazepines or phenylalkylamines. In fact, there is scope for a
broad spectrum of responses to LTCC blockers. This is because there
is negative allosteric coupling between the dihydropyridine site
and the phenylalkylamine sites (i.e., diltiazem binding is reduced by
phenylalkylamines), whereas the dihydropyridine and benzothia-
zepine sites are positively coupled (i.e., dihydropyridine binding is
increased by benzothiazepines) (see: Rosenzweig-Lipson and
Barrett, 1995).
LTCC blockers consistently prevent a BayK 8644-induced in-
crease inmonoamine release (Middlemiss,1985; Pullar and Findlay,
1992; Dobrev and Andreas, 1997; El Ayadi et al., 2001; Zhu et al.,
2004). By contrast, they do not have any prominent effects on Kþ-
induced release of monoamines (c.f., Nordström et al., 1986;
Pileblad and Carlsson, 1986; Viveros et al., 1996). On this basis, it
has been suggested that the effects of LTCC blockade on mono-
amine transmission are especially important during states of
heightened arousal (e.g., during stress), which recruit activated
LTCCs (Schenberg et al., 2000; Zhu et al., 2004). This could explain
why systemic doses of LTCC-blockers that do not affect sponta-
neous locomotor activity (e.g., Czyrak et al., 1990; Cohen et al., 1997;
Zhang et al., 2003) can increase motor activity in the forced swim
and tail suspension tests (Tazi et al., 1991; Cohen et al., 1997), which
again predicts beneﬁcial effects in treating motor retardation in
depression (Busquet et al., 2010; Casamassima et al., 2010).
4. L-type Ca2D(v) channels (LTCCs) inﬂuence the responses to
psychostimulants, antidepressants and NK1R antagonists
4.1. Acute response to psychostimulants
An early study of isolated snail neurones showed that cocaine
and d-amphetamine increased inward Ca2þ currents, a response
thought to be mediated by LTCCs (Vislobokov et al., 1993). Since
then, there have been remarkably few studies of how the response
to psychostimulants might be inﬂuenced by LTCCs. There is one
report that the dopamine response to cocaine is prevented by
dihydropyridines, but not other classes of LTCC-blockers (Pani et al.,
1990). There is no evidence that psychostimulants bind to these
channels and so it was inferred that cocaine activates
dihydropyridine-sensitive LTCCs indirectly. If so, this action could
contribute to the prominent increase extracellular serotonin and
dopamine induced by cocaine (Fig. 1).
As regards the inﬂuence of LTCCs on the behavioural response to
psychostimulants, some reports suggest that dihydropyridines and
diltiazem prevent cocaine-induced hyperactivity but not that
induced by d-amphetamine (Moore et al., 1993; Ansah et al., 1993,
2002), which again points to activation of LTCCs by cocaine. Others
have found LTTC-blockers do not affect the behavioural response to
either cocaine (Rogério and Takahashi, 1990) or d-amphetamine
(Rosenzweig-Lipson and Barrett, 1995; Bourson et al., 1989),whereas a primate study found that verapamil prevented certain
spontaneous or d-amphetamine-induced behaviours (aggression,
hypervigilance, stereotypy, oral hyperkinesia and tachypnoea) but
not others (Palit et al., 2001). However, LTCC blockers from different
classes produce distinct shifts in the dose/response proﬁles for
motor behaviour triggered by BayK 8644 and psychostimulants
(Rosenzweig-Lipson and Barrett, 1995). This is likely to be because
of differences in their allosteric modulation of LTCC function (Sec-
tion 3.2).
Clearly, there is a need for more research in this area to reconcile
these disparate reports.4.2. Chronic treatment with psychostimulants (sensitization)
There is stronger evidence that LTCCs contribute to the behav-
ioural sensitization that develops on chronic administration of
psychostimulants. This is not least because repeated administration
of the LTCC-activator, BayK 8644, alone, sensitizes rats to a subse-
quent dose of cocaine (Licata et al., 2000).
All classes of LTCC blockers prevent the development and/or
expression of behavioural sensitization to d-amphetamine at doses
that do not affect the response to acute treatment (Karler et al.,
1991; Pierce et al., 1998). LTCC-blockers also prevent develop-
ment of d-amphetamine-induced conditioned place preference
(Pucilowski et al., 1993, 1995). Even verapamil prevented the
enhanced dopamine response to locally infused d-amphetamine in
cocaine-sensitized rats (Pierce et al., 1998), despite its poor pene-
tration of the brain.
This evidence that LTCCs are needed to develop and/or express
behavioural sensitization to psychostimulants is underpinned by
studies of (null-function) Ca(v)1.2/ or Ca(v)1.3/mice (reviewed
by: Striessnig et al., 2006). Foremost is the ﬁnding that Ca(v)1.3/
mice do not develop sensitization to d-amphetamine (Giordano
et al., 2006). By contrast, Ca(v)1.2/ mice do develop sensitiza-
tion to cocaine and amphetamine. However, expression of sensiti-
zation is prevented by nifedipine in wildtypes but not Ca(v)1.2/
mice (Giordano et al., 2010). This could be explained if activation of
Ca(v)1.2 channels leads to inhibition of Ca(v)1.3 channel-opening
(Fig. 1).
Overall, these ﬁndings suggest that Ca(v)1.3 channels are
essential for development and/or expression of behavioural sensi-
tization to psychostimulants and that blockade of Ca(v)1.2 channels
prevents expression of a pre-existing sensitized response
(Giordano et al., 2010). It is interesting that Ca(v)1.3 channels,
which augment noradrenaline and dopamine release (as do psy-
chostimulants), are essential for development of sensitization
during chronic treatment with psychostimulants. The possibility
that this sensitization rests on an increase in catecholamine release
following activation of Ca(v)1.3, versus some other downstream
factor, merits further investigation.
This proposal prompts the question of what endogenous factor
could link psychostimulants with activation of LTCCs? Substance P
is a promising candidate not least because low doses of metham-
phetamine increase the concentration of extracellular substance P
in the striatum (Hanson et al., 2002) and d-amphetamine increases
immunoreactive substance P in the ventral striatum (Furmidge
et al., 1993). Furthermore, local infusion of substance P into the
striatum increases dopamine efﬂux (Reid et al., 1991) whereas
infusion of the NK1R antagonist, L 733060 prevents a cocaine-
induced increase in extracellular dopamine (Kraft et al., 2001;
Loonam et al., 2003). It seems that release of substance P, acting
via NK1R, could augment the dopamine response to psychosti-
mulants. In fact, it has even been suggested that substance P has
psychogenic actions, along the lines of psychostimulants (Kombian
S.C. Stanford / Neuropharmacology 87 (2014) 9e1814et al., 2003). Evidence that binding of substance P to NK1R activates
LTCCs is discussed below (Section 4.3).
4.3. Antidepressants
A report that LTCCs are targeted by antidepressants emerged
from the ﬁnding that antidepressants from different classes
blunted the response of the guinea-pig ileum to substance P, an
action that was attributed to convergence of their effects on LTCCs
(Boselli et al., 2007). Although it is the Ca(v)1b splice variant that is
expressed in intestinal smooth muscle, antidepressants also pre-
vent LTCC-opening in synaptosomes derived from several regions
of the forebrain, which will express mainly the Ca(v)1.2c and/or
Ca(v)1.3 subtypes (e.g., Deák et al., 2000; Lavoie et al., 1994, 1997).
Furthermore, mice with functionally inactivated Ca(v)1.3/
show less immobility than their wildtypes in the swim test
(Sinnegger-Brauns et al., 2004), suggesting that activation of Ca(v)
1.3 channels exacerbates this immobility (Fig. 1). Indeed, this is
consistent with the ﬁnding that BayK 8644 increases the immo-
bility of Ca(v)1.2/mice in this test (Sinnegger-Brauns et al., 2004).
However, a reduction in immobility in Ca(v)1.3/ mice does not
rule out the possibility that activation of Ca(v)1.2 increases motor
activity directly and/or inhibits the immobility induced by Ca(v)1.3
channel-opening (Fig. 1).
The lack of any difference in spontaneous activity of Ca(v)1.3/
mice and their wildtypes (Busquet et al., 2010) suggests that
reduced immobility (increased motor activity) in Ca(v)1.3/ mice,
compared with wildtypes, is apparent only when the animals are
aroused or stressed, as would be the case in the swim test (Benedict
et al., 1979; Stanford,1995,1996b). Blockade of Ca(v)1.3 channels by
antidepressants could contribute to the reduction in immobility in
these preclinical behavioural screens, therefore. Such an action
would distinguish antidepressants from psychostimulants, which
seem to augment rather than blunt LTCC-activation.
4.4. NK1R antagonists
The evidence that activated Ca(v)1.3 channels increase immo-
bility in the swim test (Sinnegger-Brauns et al., 2004) again points
to Substance P as an endogenous factor that triggers this process
during arousal/stress. First, release of substance P in the region of
the locus coeruleus, at least, is increased by stress (e.g., Ebner and
Singewald, 2007). Secondly, there is evidence that this peptide
opens LTCCs: an action mediated by Gq/11 protein-coupled NK1R
(Endoh, 2006). There is the additional possibility that activation of
NK1R blunts Ca(v)1.2 channel opening, which would disinhibit
immobility mediated by Ca(v)1.3 channels (Fig. 1).
If, as proposed, substance P augments Ca(v)1.3 channel-opening,
then selective NK1R antagonists would diminish this response by
blocking the cascade that couples activation of NK1R with these
channels (Fig. 1). In view of evidence that activation of Ca(v)1.3
channels augments noradrenaline and dopamine, but not seroto-
nin, release (see: Section 3.1), NK1R antagonists would be predicted
to diminish the catecholamine response, but not the serotonin
response, to arousal/stress (Fig. 1). Indeed, this could explain the
prevention of the dopaminergic and noradrenergic, but not sero-
tonergic, response to stress in mice lacking functional NK1R (Sec-
tion 2; Fig. 1). Non-selective NK1R antagonists would be expected
to be even more effective inhibitors of the immobility and cate-
cholamine response during arousal/stress. This is because the ef-
fects of Ca(v)1.3 channel blockade on these responses would be
additive with those of NK1R antagonism.
The evidence that NK1R antagonists blunt the catecholamine
response, but augment the serotonergic response, to stress suggests
that the functional coupling of these NK1R to Ca(v)1.2 (augmentsserotonin and dopamine release) and Ca(v)1.3 (augments
noradrenaline and dopamine release) recruits different second
messengers, or neuronal networks, or both. The scheme in Fig. 1
explains how the inﬂuences of these channels could converge in
the regulation of motor activity during stress. Evidence described in
the next section suggests that activation of LTCCs is also involved in
the modulation of motor impulsivity by NK1R.
5. Implications for the causes and treatment of ADHD
The possibility that a functional network, along the lines of that
proposed in Fig. 1, could affect response control, as well as stress-
induced motor behaviour, has emerged from recent studies of
genetically-altered mice that lack functional NK1R (NK1R/).
As described above, regulation of catecholamine and serotonin
release is disrupted in both NK1R/mice and wildtypes that have
been treated with an NK1R antagonist (see Section 2). NK1R/
mice also express locomotor hyperactivity (Yan et al., 2010).
Furthermore, when tested in the 5-Choice Serial Reaction Time Task
(5-CSRTT), NK1R/ mice displayed deﬁcits in cognitive perfor-
mance and response control (Yan et al., 2011). Speciﬁcally, NK1R/
mice carried outmore premature responses (an index of impulsivity)
and omission errors (an index of inattentiveness) than wildtypes.
Because hyperactivity, impulsivity and inattentiveness are core
diagnostic features of ADHD, we have proposed that impairment of
NK1R function disrupts cognitive performance/response control in
these mice and could do so in ADHD patients also. This is supported
by evidence that the TACR1 gene (the human equivalent of NK1R) is
associated with ADHD, with four markers showing allelic associa-
tion. Two haplotypes were also associated with ADHD, suggesting
more than one disease mutation (Yan et al., 2010).
These ﬁndings led us to propose that behavioural abnormalities
of NK1R/ mice should be replicated in wildtypes that have been
treated with an NK1R antagonist (RP 67580 or L 733060). As pre-
dicted, both these drugs increased locomotor activity in wildtypes,
but not NK1R/ mice (Yan et al., 2010). However, the behavioural
effects of these antagonists in the 5-CSRTT were more complex.
Whereas a low dose of either RP 67580 or L 733060 exacerbated
premature responses by wildtypes, a higher dose of either drug
prevented this increase (Weir et al., 2013). Moreover, the higher
dose of RP 67580 increased omission errors in both genotypes.
Because this increase occurred in both mouse genotypes, we
inferred that it might have arisen from blockade of LTCCs by the
(non-selective) NK1R antagonists and that LTCC-blockade could
also mask the increase in premature responses induced by the lower
drug doses. This proposal was conﬁrmed by another study inwhich
the LTCC-blocker, nifedipine, similarly reduced premature responses
and increased omission errors in both NK1R/ and wildtype mice
(Dudley et al., 2013).
It is widely accepted that disruption of serotonergic trans-
mission in corticostriatal circuits exacerbates impulsivity (e.g.,
Dalley et al., 2002). If this is the case in NK1R/ mice, then the
scheme in Fig. 1 points to premature responses arising primarily
from disruption of Ca(v)1.2 channel-opening because these chan-
nels augment serotonin release. This is supported by the additional
ﬁnding that the potency of nifedipine for reducing premature re-
sponses was lower in NK1R/ mice than the wildtypes (Dudley
et al., 2013). This could be explained by a compensatory increase
in LTCC activation in NK1R/ mice, which would echo ﬁndings in
studies that have compared the Spontaneously Hypertensive Rat
(SHR), an established rodent model of ADHD, with their Wistar
Kyoto (WKY) controls (Ohya et al., 1998; Pratt et al., 2002). It would
also ﬁt with the greater density of [3H]nitrendipine binding sites in
the striatum of SHR rats, compared with their WKY controls (Ross
and Monis, 1988). Alternatively, because nifedipine has greater
S.C. Stanford / Neuropharmacology 87 (2014) 9e18 15efﬁcacy at Ca(v)1.2 channels, the lower potency of this drug in
NK1R/mice could reﬂect a shift to a greater inﬂuence of Ca(v)1.3
channels on this behaviour (see: Sinnegger-Brauns et al., 2009).
Collectively, this evidence further indicates that LTCC blockers
could have beneﬁcial effects in treating ADHD. Indeed there is
already evidence to support this proposal in rats (Meneses and
Hong, 1998), adult humans (Schwartz et al., 1997; Hanyu et al.,
2007) and children with renal hypertension (Krause et al., 2009).
The ﬁndings described here suggest that LTCC-blockers might be
most effective in relieving the predominantly hyperactive/impul-
sive subtype of this disorder.
However, it is possible that these channels modulate attention
as well as motor activity and response control. Noradrenergic
transmission from the locus coeruleus to the prefrontal cortex has a
key role in regulating this aspect of cognitive performance (Aston-
Jones et al., 1999; Dayan and Yu, 2006). Expression of Ca(v)1.3-
channels is comparatively dense in brainstem regions, especially
in the locus coeruleus andmotor nuclei (Sukiasyan et al., 2008), and
all noradrenergic cell bodies in the locus coeruleus express NK1R
(Ma and Bleasdale, 2002).
6. Conclusions
The evidence outlined in this article suggests that NK1R an-
tagonists increase motor activity, as do psychostimulants, and
prevent immobility in the swim test, as do both psychostimulants
and antidepressants. NK1R antagonists also resemble antidepres-
sants in that they augment release of serotonin but, unlike anti-
depressants and psychostimulants, they seem to blunt the
catecholamine response during arousal. This makes it unlikely that
NK1R antagonists qualify as either antidepressants or psychosti-
mulants, but points to their forming a new class of compounds:
‘motor disinhibitors’.
The neurochemical and behavioural responses to psychosti-
mulants (during sensitization, at least), antidepressants and NK1R
antagonists during arousal/stress, all seem to involve Ca(v)1.2 and
Ca(v)1.3 channels to some extent. These channels preferentially
augment impulse-dependent release of serotonin and noradrena-
line, respectively, especially during arousal. Published ﬁndings
point to the possibility that Ca(v)1.2 channels predominantly
augment motor motivation, which reﬂects evidence thatFig. 2. The association between serotonergic and catecholaminergic transmission and
impulsivity/motor activity suggests that Ca(v) 1.2 and Ca(v)1.3 channels could have a
key role in governing a continuum of motor behaviour, ranging from psychomotor
retardation (depression) to high impulsivity/hyperactivity (ADHD). Channel labelling:
red ¼ low channel activation; green ¼ high channel activation.serotonergic transmission in the brain gates motor activity: i.e.,
response control (Jacobs and Azmitia, 1992). On the other hand,
Ca(v)1.3 channels seem to inﬂuence motor activity more directly.
As part of an integrated network, convergence of NK1R on these
two LTCCs could inﬂuence a spectrum of motor responses to stress.
A lack of motivation to respond versus excessive motivation
(impulsivity), inﬂuenced by Ca(v)1.2 channels, would interact with
immobility versus hyperactivity, inﬂuenced by Ca(v)1.3 channels
(Fig. 2). If this is the case, it is possible that the psychomotor
retardation in depression and motor hyperactivity/impulsivity in
ADHD reﬂect opposite poles of a behavioural continuum.
To understand the functional interaction between NK1R and
Ca(v) channels and their role in the regulation of motor behaviour
could hold the key to explaining why psychostimulants augment
the motor response to stress (e.g., the swim test) and yet have
beneﬁcial (calming) effects in ADHD and why antidepressants offer
little, if any, beneﬁt in treating this disorder.
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